DelveInsight’s “Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Idiopathic Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Membranous Nephropathy Market Forecast
Some of the key facts of the Idiopathic Membranous Nephropathy Market Report:
- The Idiopathic Membranous Nephropathy market size was valued approximately USD 220 million in 2022 (7MM + China) and is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In October 2023, the US FDA awarded Breakthrough Therapy Designation to felzartamab for primary membranous nephropathy (PMN) following encouraging clinical results from M-PLACE, a Phase II study conducted by I-Mab partner HI-Bio.
- In June 2023, Cerium Pharmaceuticals revealed that the US FDA awarded orphan drug designation (ODD) to SNP-ACTH (1-39) Gel.
- According to research conducted by Storrar et al. (2022), a total of 178 individuals diagnosed with primary membranous nephropathy were tracked over a span of two decades. The findings revealed that remission, whether partial or complete, was attained in 134 patients (75.3%). Among them, 60 (33.7%) experienced spontaneous remission, while 74 (41.6%) achieved remission following treatment with immunosuppressive therapy. However, out of those who achieved remission, 57 individuals (42.5%) experienced a relapse of the condition.
- In 2023, it was observed that the number of individuals with Idiopathic Membranous Nephropathy in the United States stood at approximately 29,000. Projections indicate that this figure is expected to rise to 31,227 cases by the year 2034.
- In 2023, Japan recorded an estimated 16,000 cases of Idiopathic Membranous Nephropathy.
- In 2022, the United States had the largest share, approximately 41%, of prevalent cases of Idiopathic Membranous Nephropathy (IMN) among the 7 Major Markets (7MM).
- In 2022, EU4 and the UK collectively represented around 24,000 cases of Idiopathic Membranous Nephropathy (IMN), and it is anticipated that these numbers will rise by the year 2032.
- In 2022, France had the smallest prevalence of Idiopathic Membranous Nephropathy (IMN) cases among EU4 and the UK, with approximately 4,000 cases. According to DelveInsight’s projections, these cases are anticipated to rise by 2032.
- Key pharmaceutical companies actively engaged in the development of therapies for Membranous Nephropathy (MN) include Hoffmann-La Roche (with obinutuzumab), MorphoSys (fezlartamab), Cerium Pharmaceuticals (SNP-ACTH [1-39] Gel), BeiGene (zanubrutinib), and GlaxoSmithKline.
- Key Idiopathic Membranous Nephropathy Companies: MorphoSys, , Hoffmann-La Roche, BeiGene, Cerium Pharmaceuticals, Reistone Biopharma/Eternity Bioscience, GlaxoSmithKline, ValenzaBio/ACELYRIN, Genentech, Inc., Mallinckrodt, HI-Bio, Zai Lab Pty. Ltd., ACELYRIN Inc, Reistone Biopharma, and others
- Key Idiopathic Membranous Nephropathy Therapies: Felzartamab (MOR202), GAZYVA (obinutuzumab), BRUKINSA (zanubrutinib), SNP-ACTH (1-39) Gel, SHR1459 (edralbrutinib), BENLYSTA (belimumab), VB119, Rituximab, Repository Corticotropin Injection, MOR202, efgartigimod IV, VB119, SHR1459, and others
- The Idiopathic Membranous Nephropathy epidemiology based on gender analyzed that Membranous nephropathy has a predilection for males over females.
- The Idiopathic Membranous Nephropathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Idiopathic Membranous Nephropathy pipeline products will significantly revolutionize the Idiopathic Membranous Nephropathy market dynamics.
Idiopathic Membranous Nephropathy Overview
Idiopathic Membranous Nephropathy (IMN) is a kidney disorder characterized by inflammation of the glomeruli, which are the small filtering units in the kidneys responsible for removing waste and excess fluids from the blood. In IMN, the glomeruli’s filtering membranes become thickened, and the condition is associated with the formation of immune deposits, specifically immunoglobulin G (IgG) antibodies, on the glomerular basement membrane.
Get a Free sample for the Idiopathic Membranous Nephropathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-imn-market
Idiopathic Membranous Nephropathy Epidemiology
Idiopathic Membranous Nephropathy (IMN) is a kidney disorder characterized by inflammation and thickening of the glomerular basement membrane, which is a critical component of the kidney’s filtering system. In IMN, the immune system mistakenly attacks the glomerular basement membrane, leading to proteinuria (excessive protein in the urine) and impaired kidney function.
Idiopathic Membranous Nephropathy Epidemiology Segmentation:
The Idiopathic Membranous Nephropathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalence of Idiopathic Membranous Nephropathy
- Prevalent Cases of Idiopathic Membranous Nephropathy by severity
- Gender-specific Prevalence of Idiopathic Membranous Nephropathy
- Diagnosed Cases of Episodic and Chronic Idiopathic Membranous Nephropathy
Download the report to understand which factors are driving Idiopathic Membranous Nephropathy epidemiology trends @ Idiopathic Membranous Nephropathy Epidemiology Forecast
Idiopathic Membranous Nephropathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Membranous Nephropathy market or expected to get launched during the study period. The analysis covers Idiopathic Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Idiopathic Membranous Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Idiopathic Membranous Nephropathy Therapies and Key Companies
- Felzartamab (MOR202): MorphoSys
- GAZYVA (obinutuzumab): Hoffmann-La Roche
- BRUKINSA (zanubrutinib): BeiGene
- SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
- SHR1459 (edralbrutinib): Reistone Biopharma/Eternity Bioscience
- BENLYSTA (belimumab): GlaxoSmithKline
- VB119: ValenzaBio/ACELYRIN
- Rituximab: Genentech, Inc.
- Repository Corticotropin Injection: Mallinckrodt
- MOR202: HI-Bio
- efgartigimod IV: Zai Lab Pty. Ltd.
- VB119: ACELYRIN Inc.
- SHR1459: Reistone Biopharma
Discover more about therapies set to grab major Idiopathic Membranous Nephropathy market share @ Idiopathic Membranous Nephropathy Treatment Landscape
Idiopathic Membranous Nephropathy Market Strengths
- The availability of assays for PLA2R antibodies has induced a dramatic change of the diagnostic strategy, owing to the very high specificity of anti-PLA2R antibody for the diagnosis of MN.
- With better efficacy results, and proteinuria reduction observed in six months after therapy, MOR202 (felzartamab) is expected to emerge as a strong therapeutic candidate and generate decent market share.
Idiopathic Membranous Nephropathy Market Opportunities
- Absence of marketed therapy in treatment space along with increasing patient pool paves the way for pharma players to come up with efficacious and cost effective treatment options
- High rate of progression and remission in patients with MN presents pharmaceutical companies with an opportunity to develop therapies to overcome the shortcomings and grab a highly untapped market.
Scope of the Idiopathic Membranous Nephropathy Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Idiopathic Membranous Nephropathy Companies: MorphoSys, , Hoffmann-La Roche, BeiGene, Cerium Pharmaceuticals, Reistone Biopharma/Eternity Bioscience, GlaxoSmithKline, ValenzaBio/ACELYRIN, Genentech, Inc., Mallinckrodt, HI-Bio, Zai Lab Pty. Ltd., ACELYRIN Inc, Reistone Biopharma, and others
- Key Idiopathic Membranous Nephropathy Therapies: Felzartamab (MOR202), GAZYVA (obinutuzumab), BRUKINSA (zanubrutinib), SNP-ACTH (1-39) Gel, SHR1459 (edralbrutinib), BENLYSTA (belimumab), VB119, Rituximab, Repository Corticotropin Injection, MOR202, efgartigimod IV, VB119, SHR1459, and others
- Idiopathic Membranous Nephropathy Therapeutic Assessment: Idiopathic Membranous Nephropathy current marketed and Idiopathic Membranous Nephropathy emerging therapies
- Idiopathic Membranous Nephropathy Market Dynamics: Idiopathic Membranous Nephropathy market drivers and Idiopathic Membranous Nephropathy market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Idiopathic Membranous Nephropathy Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Membranous Nephropathy Market Access and Reimbursement
To know more about Idiopathic Membranous Nephropathy companies working in the treatment market, visit @ Idiopathic Membranous Nephropathy Clinical Trials and Therapeutic Assessment
Table of Contents
1. Idiopathic Membranous Nephropathy Market Report Introduction
2. Executive Summary for Idiopathic Membranous Nephropathy
3. SWOT analysis of Idiopathic Membranous Nephropathy
4. Idiopathic Membranous Nephropathy Patient Share (%) Overview at a Glance
5. Idiopathic Membranous Nephropathy Market Overview at a Glance
6. Idiopathic Membranous Nephropathy Disease Background and Overview
7. Idiopathic Membranous Nephropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Idiopathic Membranous Nephropathy
9. Idiopathic Membranous Nephropathy Current Treatment and Medical Practices
10. Idiopathic Membranous Nephropathy Unmet Needs
11. Idiopathic Membranous Nephropathy Emerging Therapies
12. Idiopathic Membranous Nephropathy Market Outlook
13. Country-Wise Idiopathic Membranous Nephropathy Market Analysis (2020–2034)
14. Idiopathic Membranous Nephropathy Market Access and Reimbursement of Therapies
15. Idiopathic Membranous Nephropathy Market Drivers
16. Idiopathic Membranous Nephropathy Market Barriers
17. Idiopathic Membranous Nephropathy Appendix
18. Idiopathic Membranous Nephropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/